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Endothelial cell seeding has been successful in reducing the thrombogenecity of prosthetic vascular grafts in animal models, 
but results from clinical trials have been largely disappointing. These poor results have been associated with poor graft 
coverage in immediate seeding trials, and failure of ceil culture in staged procedures. These problems could be largely 
overcome by utilising a bank of allogeneic endothelial cells, providing an ever ready supply. However, one potential pitfall 
with this technique would be the possibility of a rejection response following transplantation. 
Aim: To study the effects of prolonged tissue culture, on the ability of endothelial cells to generate an immune 
response. 
Methods and results: The immunogenecity of human umbilical vein endothelial cells was measured using the mhced 
lymphocyte ndothelial reaction. It was demonstrated that prolonged tissue culture significantly reduced the 
immunogenecity of the cells, from a mean of 7261 cpm (S.E. + 243, n = 3) for cells of subculture 3, to 5478 cpm ( + 156, 
p = 0.04)for cells of subculture 7 (p = 0.04, Wilcoxon paired rank test), but did not significantly impair morphologyor 
antithrombotic function. 
Conclusion: This study provides evidence that prolonged tissue culture provides morphologically and functionally intact, 
immunomodified ndothelial cells which may potentially be used in seeding prosthetic vascular grafts. 
Key Words: Endothelial seeding; Endothelial cells: Immunomodulation; Tissue culture. 
Introduction 
Endothelial cell seeding of prosthetic vascular grafts 
has been postulated to reduce graft thrombogenecity 
and to improve long-term patency. Although results 
from studies using animal models have been suppor- 
tive, 1-3 clinical trials have been unconvincing. 4-7 These 
poor results have been associated with inadequate cell 
harvest from autologous aphenous vein and con- 
sequent poor coverage of the graft surface, s'9 One 
technique to overcome these problems would be to 
utilise a store of endothelial cells. However, this would 
necessitate he use of either a staged procedure or the 
use of readily available allogeneic endothelial cells. 
The staged technique requires two invasive proce- 
dures, the excision of a length of vein for harvesting 
endothelial cells, and at a later stage, the implantation 
of the seeded graft. 1° This technique results in a 
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considerable time delay while the cells are grown in 
culture, and may thus be unsuitable in patients with 
critical leg ischaemia. 
To overcome the delay between harvest and cell 
seeding, a bank of stored allogeneic endothelial cells 
could be utilised. Endothelial cells are easily harvested 
from vein segments and are readily grown in tissue 
culture to provide the large numbers of cells required 
for confluent coverage of graft surfaces) 1 One factor 
limiting the use of allogeneic cells is the potential 
rejection response that may occur following trans- 
plantation, particularly since endothelial cells have 
been demonstrated to be capable of antigen presenta- 
tion. 12-17 Many immunomodulatory techniques have 
developed with the advent of transplantation surgery 
and it has been suggested that prolonged tissue 
culture may have the potential to reduce the ability of 
endothelial cells to initiate an immune rejection 
response. 18 
In this study, we examined whether prolonged 
tissue culture could reduce the immunogenecity of
endothelial cells and make allogeneic endothelial cell 
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seeding of prosthetic vascular grafts a feasible proce- 
dure. The mixed lymphocyte endothelial culture 
(MLEC) was used to investigate endothelial cell 
immunogenecity. Culture of lymphocytes from two 
histo-incompatible donors results in each set reacting 
against the foreign histocompatibility antigens 
expressed by the other. The responding cells become 
lymphoblasts and begin DNA synthesis and mitosis. 
This proliferative response usually reaches a peak 
after 5-7 days in culture and may be quantified by the 
uptake of tritiated thymidine. By rendering one set of 
lymphocytes incapable of proliferation, by treatment 
with mitomycin C, a one way mixed lymphocyte 
reaction (MLR) may be performed, which is a measure 
of the degree to which the responding cells react 
against he histocompatibility antigens present on the 
inactivated stimulator cells. 
The MLR is the only in vitro model for the 
recognition of foreign major histocompatibility com- 
plex (MHC) gene products by T cells, and is a reliable 
and valid predictive test for cell mediated immune 
responses. 19The classical MLR may be adapted to 
determine the immunogenic potential of endothelial 
cells to provoke a primary proliferative response by T 
lymphocytes. This is termed the mixed lymphocyte 
endothelial cell culture (MLEC). ~5 
The immunogenecity of antigen presenting cells is 
dependent on their ability to present antigen in 
association with MHC class I and II molecules, 2°and 
therefore, endothelial cell expression of MHC class I 
and II was analysed using flow cytometry. Basal 
release of gamma interferon (IFN-2) is greatly 
enhanced in inflammatory conditions 2~ and is known 
to affect antigen expression by endothelial cells, 
notably by increasing MHC class II antigen expres- 
sion. 22 It is possible that augmented IFN-2 release may 
affect he immunogenecity of endothelial cells seeded 
on the luminal surface of a prosthetic vascular graft. A 
comparison was made between IFN-2 and non-IFN- 7 
stimulated endothelial cell cultures in terms of both 
stimulatory capacity in vitro (MLEC) and MHC class I
and II expression. 
Materials and Methods 
Isolation and culture of endothelial cells 
Endothelial cells were isolated from human umbilical 
veins, and then subsequently grown in tissue culture 
as has been previously described. 23The endothelial 
cells were passaged when confluence was reached to 
obtain the various subcultures required for the 
study. 
Identification of endothelial cells 
Cells isolated from umbilical veins were identified by 
phase contrast and electron microscopy, n'24 Addition- 
ally a rabbit anti-human von Willebrand Factor (vWF) 
antibody (Dakopatts, High Wycombe, U.K.) specific 
for vWF, and a mouse monoclonal directed against a 
specific endothelial cell surface component, QB-END/ 
40.1, (Quantum Biosystems Ltd, Cambridge, U.K.) 
were utilised to confirm endothelial identity. 
Experimental design. The human mixed lymphocyte 
reaction (MLR) and mixed lymphocyte ndothelial cell 
culture (MLEC) 
The MLEC was performed using endothelial cells 
isolated from different stages of tissue culture in order 
to detect any change in immunogenecity with cell 
culture. Non IFN-y treated and IFN-y treated endothe- 
lial cells of subcultures 3, 5, and 7, all originally from 
the same umbilical vein, were used as the stimulating 
cells. The MLEC was repeated using cells isolated 
from three umbilical veins, with three experiments 
being performed for each subculture studied, in both 
stimulated and unstimulated states. 
Isolation of lymphocytes 
Lymphocytes were separated from heparinised 
human blood from four separate healthy donors, by 
the Ficoll Isopaque flotation method. Ten millilitres of 
human blood were diluted in a 1:1 ratio with MEM 
and layered onto 20 ml of Ficoll lymphocyte separa- 
tion media (Flow Labs, Irvine, U.K.) in a 50 ml conical 
polypropylene centrifuge tube. The tube was spun at 
2000 rpm and 18-22°C for 20 min. Lymphocytes were 
harvested from the plasma-Ficoll interface by aspira- 
tion and washed twice with MEM supplemented with 
5% fetal calf serum (FCS) by centrifugation (2000 rpm, 
4°C 10 rain). The number of viable lymphocytes 
recovered were quantified by trypan blue exclusion. 
Of the four samples, three sets of lymphocytes were 
resuspended in RPMI at a concentration of lx106 
cells/ml. The fourth set was set aside for mitomycin 
treatment. 
Gamma interferon treatment of endothelial cells 
Human umbilical venous endothelial cells in tissue 
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culture were incubated with 1000 units of IFN-7 per 
ml of medium for 72 h at 37°C in 5%CO2/95%air. The 
stimulated cells were then treated in an identical 
method to unstimulated endothelial cells. 
Mitomycin treatment of lymphocytes and endothelial cells 
One set of lymphocytes, designated stimulator lym- 
phocytes, and both IFN-y stimulated and unstimu- 
lated endothelial cells of subcultures 3,5, and 7, were 
subjected to mitomycin treatment in order to destroy 
their proliferative capacity. 
The cells were resuspended in a volume of lml of 
MEM at a concentration f 2 × 106 cells/ml. Mitomy- 
cin (Sigma, Poole, U.K.), was added at a concentration 
of 25 ~g/ml and the cells incubated at 37°C in air for 
30 min prior to being washed three times in MEM 
supplemented by 5% FCS (200 × g, 4°C, 7 rain). The 
cells were then resuspended in RPMI at 1 × 106 cells/ 
ml. 
Mixed lymphocyte and mixed lymphocyte ndothelial cell 
cultures 
Cell cultures were set up in round bottomed microtitre 
plates (NUNC, Roskilde, Denmark) in quadruplicate, 
using 1 × 105 responder lymphocytes with equal 
numbers of mitomycin treated stimulator lympho- 
cytes or mitomycin treated endothelial cells (exposed 
and unexposed to IFN-y). Responder lymphocytes, 
stimulator lymphocytes, and endothelial cells were 
cultured alone to determine their basal rate of DNA 
synthesis. Responder lymphocytes were cultured with 
a mitogen, concavalin A (100 ~1 of a 4 mg/ml  solution 
made up in RPMI) (Sigma, Poole, U.K.) to ascertain 
their capacity to proliferate. Responder and stimulator 
lymphocytes were used from the same donors for each 
experiment and IFN-y exposed and unexposed endo- 
thelial cells of each subculture were from the same 
umbilical vein. Each experiment was repeated in 
triplicate. 
The cultures were incubated for Various periods of 
time, ranging from 2-9 days and labelled with l~Ci of 
3H Thymidine (Amersham International, Little Chal- 
font, U.K.) on days 2, 3, 5, 7, and 9. After 18 h the cells 
were harvested by aspiration onto glass fibre filters 
and the wells sequentially washed with distilled water 
and 50% methanol using a semi-automated harvester, 
(SkatronAs, Oslo, Norway). The filter strips were 
dried overnight at room temperature and each indi- 
vidual filter disc placed in a scintillation vial the 
following morning. Two millilitres of scintillation 
fluid (OptiScint Safe, FSA Laboratory Supplies, 
Loughborough, U.K.) were added to each vial and the 
uptake of the radioactive label determined using a 
beta scintillation counter (1217 RackBeta, LKB Instru- 
ments Ltd, South Croydon, U.K.). 
All data from the MLR-MLEC were expressed as 
mean counts per min (cpm) of quadruplicate cultures 
with standard errors. These values are measures of 
DNA synthesis and therefore correspond to the extent 
of proliferation occurring within the culture. This may 
be correlated to the ability of the stimulating cell 
source to stimulate the proliferation of allogeneic 
lymphocytes. 
Detection of MHC class I and 1I antigen expression by 
endothelial cells using the fluorescence activated cell 
sorter (FACS) 
Human umbilical venous endothelial cells were iso- 
lated and resuspended ata concentration f 2.0 × 106 
cells/ml in MEM with 5% FCS. Purified mouse IgG1 
monoclonal antibody directed towards Aspergillus 
niger glucose oxidase, (an enzyme which is neither 
present or inducible in mammalian tissues), conju- 
gated with FITC or RPE, was used as a control 
(Dakopatts, High Wycombe, U.K.). 
Rabbit immunoglobulin to human f~2-microglobulin 
conjugated with FITC was used to determine cell 
surface xpression of MHC class I antigen (Dakopatts, 
High Wycombe, U.K.), and RPE conjugated anti 
human HLA-DR immunoglobulin was used to assess 
MHC class II antigen expression (Becton Dickinson, 
New Jerse~ U.S.A.). 
One hundred microlitres of the endothelial cell 
suspension was added to 10 ~1 of each monoclonal 
antibody in 2052 FACS tubes (Becton Dickinson, New 
Jerse~ U.S.A.). The cell suspension was incubated on 
ice for 35 min and then washed twice using MEM 
supplemented by 5%FCS and 0.5% sodium azide 
(800 × g, 4°C for 10 min). The cells were resuspended 
and fixed in 0.1% glutaraldehyde. 
Analysis was performed by flow cytometry using a 
fluorescence activated cell sorter (FACS) (Becton Dick- 
inson FACS Systems, Becton Dickinson & Co., Sunny- 
vale, CA, U.S.A.), with a 100 ~m orifice to permit entry 
of endothelial sized cells. Data were obtained on both 
electronic cell volume and immunofluorescence of 
each cell passing through the orifice. Endothelia!isized 
cells form a distinct cluster on the volume or fluores- 
cence intensity plot, and gates were empirically set to 
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exclude small cells and subcellular debris from analy- 
sis. The data were based on analysis of 5 × 103 cells 
and stored on magnetic tape. It was displayed as a dot 
plot of cell number (y-axis) against log fluorescence 
intensity (x-axis). The MHC class I and II antibody 
was always compared with non-specific binding of an 
unreactive mouse monoclonal antibody of the same 
immunoglobulin class. Three replicate experiments 
were performed at each subculture in both stimulated 
and unstimulated states. 
Functional assessment of isolated endothelial cells 
Human umbilical venous endothelial cells were iso- 
lated and plated at a concentration of 1.0 × 105 cells/ 
well in a 24 well plate (Nunc, Roskilde, Denmark). 
Following 24 h of incubation in a 5%CO2/95%air 
atmosphere at 37°C, the complete culture media was 
replaced by 1 ml of plain MEM. A sample of the 
medium (100 B1) was taken after 30 rain and assayed 
for basal PGI2 release. 
After 30 min, thrombin was added to the well to 
obtain a final concentration of 1 u/ml. A second 
sample of medium was taken 10 min after the addition 
of thrombin, which was assayed for stimulated PGIz 
release. Prostacyclin concentration i the samples was 
assayed by the measurement of 6-keto prostaglandin 
FI~, the stable metabolite of PGI2 breakdown at pH7.4, 
by the use of a commercially available competitive 
radioimmunoassay kit (Amersham, Little Chalfont, 
U.K.). The experiment was repeated using endothelial 
cells isolated from subcultures 3,5, and 7, all originally 
from the same umbilical vein. Three umbilical veins 
were used. 
Statistics 
All results are presented as means with standard 
errors. Non parametric statistical analysis (Wilcoxon 
paired test and Mann-Whitney U-Test) was utilised to 
analyse continuous variables. 
Results 
Morphology of culture endothelial cells 
Endothelial cells of all subcultures examined by light 
and phase contrast microscopy demonstrated the 
cobblestone appearance characteristic of an endothe- 
lial cell monolayer. The cells stained positively for 
both von Willebrand Factor and the QB-END/40.1 
antibody. 
The MLR-MLEC interaction 
Cell numbers and viability. A mean of 2.57 × 106 ( + 0.21) 
viable lymphocytes were recovered per ml of hep- 
arinised blood collected from four consistent donors 
used for the MLR-MLEC cultures. Endothelial cells 
and lymphocytes used as stimulating cells in the 
MLECs and MLRs were treated with mitomycin C to 
destroy their proliferative capacity. Fewer than 10% of 
the cells were rendered non-viable by mitomycin C 
treatment. 
Validations. The incorporation of 3H thymidine by 
mitomycin C treated stimulator lymphocytes and 
endothelial cells cultured individually demonstrated 
that mitomycin C treatment reduced the proliferative 
capacity of these cells to a negligible level. 
All sets of responder lymphocytes displayed spon- 
taneous proliferation in culture and their ability to 
proliferate was definitively demonstrated by culture 
with concavalin A. In each case, concavalin A had a 
strong mitogenic affect on the lymphocytes and 
maximal stimulation was observed on day 3. As a 
consequence, for cultures involving responder lym- 
phocytes with stimulator cells, 3H thymidine incor- 
poration attributable to the proliferation of the 
responder cells alone in culture was subtracted from 
the value obtained for the culture with stimulator 
cells. 
The MLR-MLEC. Culture of mitomycin C treated 
lymphocytes and unstimulated endothelial cells, with 
allogeneic responder lymphocytes resulted in a max- 
imal stimulatory response on day 7 in every experi- 
ment except one. IFN-~-stimulated endothelial cells 
caused an earlier maximal response on day 5 but did 
not appear to stimulate allogeneic lymphocytes to a 
greater degree than nontreated endothelial cells. 
Mitomycin C-treated lymphocytes stimulated allo- 
geneic lymphocytes more effectively than similarly 
treated endothelial cells on a cell to cell basis. Maximal 
3H thymidine incorporation observed in the MLEC 
was expressed as a percentage of the maximal 3H 
thymidine incorporation observed in the correspond- 
ing MLR, i.e. the MLR involving the same responder 
lymphocytes as the MLEC (Table 1). The allogeneic 
response caused by endothelial cells was less than 45 % 
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Table 1. Comparison of maximal stimulation of responder 
lymphocyte proliferation by allogeneic lymphocytes to endothelial 
cells 
Endothelial cell Responder 
subculture lymphocyte % Response 
3 1 41.0 
2 40.2 
3 42.8 
5 1 34.1 
2 36.3 
3 34.1 
7 1 33.7 
2 39.5 
3 33.8 
In all cases, cell passage did not significantly affect 
class I or class II antigen expression. There was no 
significant difference in class I expression by endothe- 
lial cells of subcultures 2 or 8 (W = 11.0, d.f. = 2, 
p = 1.00, unstimulated endothelial cells ; W = 11.0, 
d.f. -- 2, p = 1.00, stimulated endothelial cells, Mann 
Whitney U Test), and similarly cell passage (sub- 
culture 2 to 8) did not significantly alter class II 
expression by either IFN-y stimulated or unstimulated 
endothelial cells (W= 10.0, d.f. =2, p---1.00 ; 
W = 15.0, d.f. = 2, p = 0.08, respectivel)~ Mann Whit- 
ney U-test). 
of that caused by stimulator lymphocytes in the 
corresponding MLR in all cases. 
The most significant finding in this study was a 
significant decrease in the stimulatory capacity of IFN- 
y-treated endothelial cells as a consequence of cell 
passage from subculture 3 to 7 (test statistic = 21.0, 
p = 0.04, Wilcoxon paired rank test). A decrease in 
stimulatory capacity of non-treated endothelial cells 
with prolonged tissue culture was apparent, but was 
not found to be statistically significant (test statis- 
tic = 18.0, p = 0.14, Wilcoxon paired rank test). 
MHC class I and II antigen expression by cultured 
endothelial cells. (Table 2) 
Analysis of MHC class I and II antigen expression by 
endothelial cells demonstrated that regardless of cell 
subculture, 997o of unstimulated endothelial cells 
bound monoclonal antibody directed against MHC 
class I antigen, whereas less than 27o bound the 
antibody directed against MHC class II HLA-DR 
antigen. 
Endothelial cells were labelled with two non- 
specific mouse monoclonal antibodies conjugated 
with RPE and FITC in order to provide controls for the 
FITC conjugated mouse anti-human class I antibody 
and the RPE conjugated mouse anti-human HLA-DR 
antibody. FACS analysis demonstrated that approx- 
imately 27o of the cells bound both the FITC and the 
RPE conjugated controls. Therefore it was difficult to 
state the percentage of cells expressing class II HLA- 
DR antigen using this system of detection. 
Stimulation of the endothelial cells with IFN-y for 72 
h significantly altered class I antigen expression 
(W = 70.5, d.f. = 2, p = 0.02, Mann Whitney U-test) 
and also induced greater than 907o of the cells to 
express class II antigens (W = 28.0, d.f. = 2, p = 0.002, 
Mann Whitney U-test). 
Prostacyclin production by cultured endothelial cells 
Results for basal and stimulated PGI 2 release by 
endothelial cells isolated from subcultures 1 to 7 are 
illustrated in Fig. 1. 
Basal PGIz release by endothelial cells of subculture 
I was 1.121 pg PGI2/105 cells/rain ( _ 0.141) and after 
thrombin stimulation increased to 14.41 pg PGI2/105 
cells/rain (_+ 1.05). Similar results were obtained for 
endothelial cells of subcultures 3, 5, and 7, with 
thrombin stimulation causing at least a ten-fold 
increase in PGIa release. 
No significant difference in basal PGI 2 release 
between endothelial cells of subcultures 1 and 7 was 
observed (W = 37.0, d.f. = 5, p = 0.81, Mann Whitney 
U-test). Similarly there was no significant difference 
for stimulated PGI2 release by endothelial cells of 
subcultures 1 and 7. (W = 46.0, d.f. = 5, p = 0.30, 
Mann Whitney U-test). 
Discussion 
Allogeneic endothelial cell seeding of prosthetic vas- 
cular grafts is an attractive method whereby confluent 
graft coverage may be achieved. However, histoin- 
compatibility between donor and recipient may be a 
limiting factor and it has been suggested that pro- 
longed tissue culture may immunomodulate endothe- 
lial cells, thereby reducing their ability to initiate an 
immune rejection response. 18 It is essential that any 
immunomodulation technique specifically alters 
immunogenecity without adverse effects on cellular 
morphology or function. As of yet, immunomodula- 
tion of endothelial cells has not been attempted in the 
context of allogeneic ell seeding of vascular grafts. In 
this stud)~ the effects of prolonged tissue culture, on 
endothelial cell morpholog34 function and immunoge- 
necity were investigated. 
Eur J Vasc Endovasc Surg Vol 10, July 1995 
106 J .K .  Desai et aL 
Table 2. MHC class I and II expression by endothelial cells of sequential subcultures. Values are means with standard er rors  
Subculture 
Unstimulated IFN-? stimulated Unstimulated IFN-? stimulated 
MHC class I MHC class II MHC class I MHC class II FITC RPE FITC RPE 
2 99.7 (0.06) 1.3 (0.04) 99.8 (0.07) 95.0 (2.45) 1.87 (0.05) 0.82 (0.21) 2.05 (0.23) 1.20 (0.04) 
3 99.8 (0.01) 1.1 (0.10) 99.4 (0.38) 95.6 (1.85) 1.56 (0.07) 1.00 (0.9) 1.89 (0,14) 1.09 (0.08) 
4 99.9 (0.08) 1.1 (0.14) 99.0 (0.86) 95.3 (1.20) 2.31 (0.06) 0.79 (0.10) 1.76 (0.15) 1.21 (0.06) 
5 99.8 (0.09) 1.0 (0.13) 99.7 (0.13) 95.6 (1.56) 1.75 (0.10) 0.65 (0.13) 1.87 (0.20) 0.98 (0.10) 
6 99.9 (0.05) 1.3 (0.13) 98.8 (1.12) 98.1 (1.19) 1.83 (0.12) 0.96 (0.08) 2.03 (0.09) 1.79 (0.10) 
7 99.8 (0.07) 0.9 (0.05) 99.6 (0.34) 95.4 (0.81) 2.03 (0.09) 0.78 (0.10) 2.12 (0.12) 1.56 (0.14) 
Prostacyclin (PGI2) is a potent inhibitor of platelet 
function and its production and release by endothelial 
cells prevents adherence of stimulated platelets to the 
vessel wall and thus reduces likelihood and extent of 
thrombus formation. 25 The capacity of an intact 
endothelial monolayer to reduce thrombogenecity n 
this manner underlies the rationale behind seeding of 
grafts with confluent monolayers of endothelial cells. 
It is therefore ssential to ensure that endothelial cells 
grown in tissue culture retain their capacity to release 
PGI2. In this studN neither basal nor stimulated PGI 2 
release by HUVEC's was significantly affected by cell 
passage. 
Endothelial cells are capable of stimulating an 
immune response in vitro as assessed by the MLECY 
The MLEC determines the stimulatory capacity of 
endothelial cells by measuring the uptake of 3H 
thymidine by cocultured allogeneic lymphocytes. A 
modified version of the MLEC was used to investigate 
the effects of cell passage on the ability of endothelial 
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Fig. 1. Graph illustrating basal and thrombin stimulated prostacy- 
clin release by human umbilical vein endothelial cells of sequential 
subcultures. Values arc means with standard error bars. (m) 
unstimulated release; ([~) thrombin stimulated. 
In all cases the proliferative response using endothe- 
lial cells as the stimulating cell source was less than 
45% of the response observed using allogeneic lym- 
phocytes. However, this response remains significant 
in terms of stimulating an immune rejection response 
in vivo. 
By far the most important finding of this study was 
that serial cell passage appeared to reduce the immu- 
nogenicity of both stimulated and unstimulated cells. 
This may prove to be of fundamental importance in 
considering the applicability of allogeneic transplanta- 
tion, but the mechanism of this reduction in immuno- 
genicity is far from clear. 
An antigen presenting cell must be capable of 
expressing antigen on its membrane surface in asso- 
ciation with class II MHC molecules in a form 
recognisable by the appropriate cells, and of providing 
the necessary costimualtory signals to cells of the 
immune system. 27'28 Productive nominal and alloanti- 
gen presentation by endothelial cells has been demon- 
strated to be associated in particular with HLA-DR, 
the immunodominant human class II antigen. ~3'14"26"27 
Therefore, endothelial cell expression of HLA-DR was 
analysed using flow cytometry. Cell passage appeared 
to have no effect on Class II antigen expression. 
This study provided evidence that repeated cell 
passage significantly reduced the ability of endothelial 
cells to stimulate an immune response without affect- 
ing class II antigen expression. These results suggest 
that endothelial cells may be immunomodif ied by 
prolonged tissue culture but that this effect is unre- 
lated to class II expression. As the reduction in 
endothelial cell immunogenecity observed has not 
been conclusively correlated with alterations in class II 
antigen expression~ it is possible that it may be related 
to less effective co-stimulation, as opposed to antigen 
presentation. A number of hypotheses may be formed 
regarding the mechanism whereby cell passage 
reduces immunogenecity of endothelial cells; how- 
ever, we cannot, without further experimental work, 
define the underlying mechanism. In conclusion, the 
results from this study suggest hat prolonged tissue 
culture produces morphologically and functionally 
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intact immunomodified human umbilical vein endo- 
thelial cells which may have the potential for seeding 
prosthetic vascular grafts. 
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